Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Drug-Receptor Interactions01:29

Drug-Receptor Interactions

Drug-receptor interaction describes the binding of receptors by drugs, but not all drug-receptor interactions result in activation and tissue response. For instance, the binding of agonists activates the receptor to generate a cellular reaction, while antagonists bind to receptors without causing their activation.
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue.
Principles of Drug Action01:24

Principles of Drug Action

Drugs are chemical substances that modify biological responses by interacting with macromolecular targets such as receptors, ion channels, transporters, and enzymes. Pharmacodynamics describes the course of action of drugs leading to the physiological effect at a specific site in the body.
Drugs can be agonists or antagonists. Like the endogenous ligands, agonists always bind and activate the target to produce a cellular response. Agonist binding induces a conformational change which in turn...
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Dose-Response Relationship: Selectivity and Specificity01:25

Dose-Response Relationship: Selectivity and Specificity

Drugs exert their therapeutic effects by interacting with receptors, enzymes, or ion channels that are present throughout the human body. The strength and duration of the interaction between a drug and its target receptor are characterized by the selectivity and specificity of the drug. Selectivity refers to a drug's strong preference for its intended target over other targets. For instance, isoprenaline, a non-selective β-adrenergic agonist, interacts with both β1- and β2-adrenergic receptors...
Drug-Receptor Interaction: Antagonist01:28

Drug-Receptor Interaction: Antagonist

An antagonist is a drug that binds strongly to a receptor without activating it. An antagonist prevents other molecules, such as neurotransmitters or hormones, from binding to the receptor and triggering a cellular response. Such interaction effectively hinders the normal physiological processes mediated by the receptor, resulting in various pharmacological effects depending on the specific receptor targeted.
Antagonists can be classified as competitive or noncompetitive based on their...
Drugs Affecting Neurotransmitter Release or Uptake01:21

Drugs Affecting Neurotransmitter Release or Uptake

Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Triphenylsulfonium topophotochemistry.

Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology·2017
Same author

Measurement of the centrality dependence of the charged-particle pseudorapidity distribution in proton-lead collisions at [Formula: see text] TeV with the ATLAS detector.

The European physical journal. C, Particles and fields·2017
Same author

Search for new phenomena in events with at least three photons collected in <i>pp</i> collisions at [Formula: see text] = 8 TeV with the ATLAS detector.

The European physical journal. C, Particles and fields·2017
Same author

Identification of boosted, hadronically decaying <i>W</i> bosons and comparisons with ATLAS data taken at [Formula: see text] TeV.

The European physical journal. C, Particles and fields·2016
Same author

Observation of Long-Range Elliptic Azimuthal Anisotropies in sqrt[s]=13 and 2.76 TeV pp Collisions with the ATLAS Detector.

Physical review letters·2016
Same author

Search for direct top squark pair production in final states with two tau leptons in <i>pp</i> collisions at [Formula: see text] TeV with the ATLAS detector.

The European physical journal. C, Particles and fields·2016

関連する実験動画

Updated: Jul 6, 2026

A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators
07:41

A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators

Published on: February 20, 2018

レチノイドX受容体の反応経路を選択するレチノイド.

J M Lehmann1, L Jong, A Fanjul

  • 1Cancer Center, La Jolla Cancer Research Foundation, La Jolla, CA 92037.

Science (New York, N.Y.)
|December 18, 1992
PubMed
まとめ

新しいレチノイドは,レチノイドX受容体 (RXRs) ホモダイマーを,レチノ酸受容体 (RARs) に独立して選択的に活性化します. これにより,異なるレチノイドシグナル伝達経路の独立した活性化が可能になります.

科学分野:

  • 分子生物学は分子生物学である.
  • エンドクリノロジー エンドクリノロジー
  • 薬理学 薬理学とは

背景:

  • レチノイドは,多様な生物学的活動を持つ重要な治療薬です.
  • レチノイドシグナル伝達は主にレチノ酸受容体 (RAR) とレチノイドX受容体 (RXR) によって媒介されます.
  • RARは通常,DNA結合と転写調節のためのRXRとヘテロダイマーとして機能する.

研究 の 目的:

  • 特定のレチノイド受容体複合体を選択的に標的にできる新しいレチノイドを開発する.
  • RAR-RXRヘテロジメとRXRホモジメの独立した活性化の可能性を調査する.
  • レチノイドシグナル伝達経路を解剖することによって,新しい治療戦略を探求する.

主な方法:

  • レチノイドの新しいシリーズの合成と特徴付け.
  • RXRホモジメとRAR-RXRヘテロジメの活性化を評価するためのインビトロアッセイ.
  • 受容体-リガンドの相互作用と下流信号効果の分析.

主要な成果:

  • 選択的にRXRホモダイマーを活性化する新しい一連のレチノイドが特定されました.
  • これらのレチノイドは,RAR-RXRヘテロジメの有意な活性化を示さなかった.

さらに関連する動画

A Flow Cytometry-based Assay to Identify Compounds That Disrupt Binding of Fluorescently-labeled CXC Chemokine Ligand 12 to CXC Chemokine Receptor 4
06:56

A Flow Cytometry-based Assay to Identify Compounds That Disrupt Binding of Fluorescently-labeled CXC Chemokine Ligand 12 to CXC Chemokine Receptor 4

Published on: March 10, 2018

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission
07:16

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission

Published on: August 16, 2018

関連する実験動画

Last Updated: Jul 6, 2026

A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators
07:41

A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators

Published on: February 20, 2018

A Flow Cytometry-based Assay to Identify Compounds That Disrupt Binding of Fluorescently-labeled CXC Chemokine Ligand 12 to CXC Chemokine Receptor 4
06:56

A Flow Cytometry-based Assay to Identify Compounds That Disrupt Binding of Fluorescently-labeled CXC Chemokine Ligand 12 to CXC Chemokine Receptor 4

Published on: March 10, 2018

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission
07:16

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission

Published on: August 16, 2018

  • RAR-RXRヘテロジマー機能に影響を与えることなく,RXRホモジマー活動の独立した調節を達成しました.
  • 結論:

    • この発見は,異なるレチノイドシグナル伝達経路を独立して活性化する可能性を示しています.
    • この選択的活性化は,レチノイドベースの治療法を微調整するための新しいアプローチを提供します.
    • 特にRXRホモダイマーをターゲットにすることで,オフターゲットの効果を減らす新しい治療介入の道が開きます.